Sevelamer hydrochloride in peritoneal dialysis patients: Results of a multicenter cross-sectional study

Peritoneal Dialysis International

Volumn 27, Issue 6, 2007, Pages 697-701

  Ramos, Rosa ^a   Moreso, Francesc ^a   Borras, Mercè ^b   Ponz, Esther ^c   Buades, Joan M ^d   Teixidó, Josep ^e   Morey, Antoni ^f   Garcia, Carme ^g   Vera, Manel ^h   Doñate, M Teresa ⁱ   Ramírez de Arellano, Manuel ^j   Barbosa, Francesc ^k   González, M Teresa ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL ARNAU DE VILANOVA   (Spain)

^c Department of Anesthesiology   (Spain)

^d HOSPITAL SON LLÀTZER   (Spain)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f HOSPITAL SON DURETA   (Spain)

^g HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ FUNDACIÓ PUIGVERT   (Spain)

^j HOSPITAL DE TERRASSA   (Spain)

^k HOSPITAL DEL MAR   (Spain)

more..

Author keywords

Phosphate binders; Sevelamer hydrochloride

Indexed keywords

ALBUMIN; BICARBONATE; C REACTIVE PROTEIN; CALCIUM; CALCIUM PHOSPHATE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; TRIACYLGLYCEROL; CALCIUM DERIVATIVE; CHELATING AGENT; POLYAMINE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BICARBONATE BLOOD LEVEL; BIOCHEMISTRY; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARATHYROID HORMONE BLOOD LEVEL; PERITONEAL DIALYSIS; PRIORITY JOURNAL; ACIDOSIS; BLOOD; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; CROSS-SECTIONAL STUDY; HYPERPHOSPHATEMIA; MIDDLE AGED; STATISTICAL MODEL;

ACIDOSIS; ADULT; AGED; BICARBONATES; CALCIUM; CALCIUM COMPOUNDS; CHELATING AGENTS; CHOLESTEROL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PHOSPHATES; POLYAMINES;

EID: 41049117434     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080702700618     Document Type: Article

References (18)

1. Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT; Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) Study Group. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for bone metabolism and disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 2005; 46: 925-32.
2. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus ad calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31:607-17.
3. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(4 Suppl 3): S1-201.
4. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, et al. Cardiac calcification in adult hemodialysis patients: a link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39:695-701.
5. Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Longterm effects of sevelamer hydrochloride on the calcium-phosphate product and lipid profile of hemodialysis patients. Nephrol Dial Transplant 1999; 14:2907-14.
6. Goldberg DI, Dillon MA, Slatopolsky EA, Garrett B, Gray JR, Marbury T, et al. Effect of Renagel®, a non-absorbed, calcium- and aluminum-free phosphate binder, on serum phosphate, calcium and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 1998; 13:2303-10.
7. Bleyer AJ, Burke SK, Dillon MM, Garrett B, Kant KS, Lynch D, et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999; 33: 694-701.
8. Gallieni M, Cozzolino M, Brancaccio D. Transient decrease of serum bicarbonate levels with sevelamer hydrochloride as the phosphate binder. Kidney Int 2000; 57:1776-7.
9. Suner M, Guerrero A, Montes R, Rivera M, Ruiz A, Martínez-García M, et al. Treatment of hyperphosphatemia with sevelamer in patients with chronic renal failure. Nefrología 2004; 24:142-8.
10. Ortiz A, Racíos F, Melero R, Reyero A, Gazapo R, Casado S. Experiencia con sevelamer en diálisis peritoneal. Nefrología 2003; 23:432-6.
11. Pagé D, Knoll G. Peritoneal dialysis patients using sevelamer do not present the acidosis problems that hemodialysis patients do. Adv Perit Dial 2005; 21:185-7.
12. Katopodis KP, Andrikos EK, Gouva CD, Bairaktari ET, Nikolopoulos PM, Takouli LK, et al. Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients. Perit Dial Int 2006; 26:320-7.
13. Charlson ME, Pompei P, Ales KL, McKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-83.
14. Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62:245-52.
15. Arenas MD, Alvarez-Ude F, Gil MT, Soriano A, Egea JJ, Millan I, et al. Application of NKF-K/DOQI Clinical practice guidelines for bone metabolism and disease: changes of clinical practices and their effects on outcomes and quality standards in three hemodialysis units. Nephrol Dial Transplant 2006; 21:1663-8.
16. Qunibi W, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004; 65:1914-26.
17. Borras M, Marco MP, Fernández E. Treatment with sevelamer decreases bicarbonate levels in peritoneal dialysis patients. Perit Dial Int 2002; 22:737-8.
18. Bommer J, Locatelli F, Satayathum S, Keen ML, Goodkin DA, Saito A, et al. Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 661-71.